ADVERTISEMENT

Clinical Summary

Breast cancer: 15-year results of fluorouracil, dose-dense chemotherapy

Miriam Davis, PhD   |   22 November 2022

Background

  • The previous 7-year results of the GIM trial, published in 2015, found that the addition of fluorouracil to chemotherapy for high-risk early breast cancer was unnecessary and more toxic and that dose-dense adjuvant chemotherapy (given every 2 weeks) delivered superior DFS and OS compared with the standard schedule chemotherapy (given every...

          

Topic Challenges

left
right